Corvus Pharmaceuticals, Inc.
CRVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001626971
No open-market purchases or sales by Corvus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 173 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Corvus Pharmaceuticals, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 52 | 48 | −4 |
| Shares | 19.2M | 19.2M | −2.90K (0.0%) |
| Value | $28.0M | $33.8M | +$5.75M (+20.5%) |
New holders (3)
Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 23,095 | $40.6K | 0.00% |
| Resources Investment Advisors, LLC. | 12,400 | $21.8K | 0.00% |
| Royal Bank of Canada | 122 | $0 | 0.00% |
Sold out (7)
Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Marshall Wace, LLP | 198,220 | $289.4K |
| Goldman Sachs Group Inc | 49,324 | $72.0K |
| Virtu Financial LLC | 17,366 | $25.0K |
| Invesco Ltd. | 15,617 | $22.8K |
| HRT Financial LP | 13,050 | $19.0K |
| Two Sigma Securities, LLC | 11,232 | $16.4K |
| FMR LLC | 1,101 | $1.61K |